Interview with Eurocine Vaccines AB's CEO Dr. Hans Arwidsson
Swedish vaccine researcher and developer Eurocine Vaccine AB opened their new rights issue for existing and new investors. IPOhub team reached out their CEO and Board Director Dr. Hans Arwidsson and we asked few questions about the company, its strategy and ongoing rights issue. What's Eurocine Vaccines AB about and who are the people behind it? Specialized in vaccine development, and with decades long experience, the highly qualified team and board of Eurocine Vaccines has a proven record to manage all aspects of vaccine development including preclinical and clinical development, scalability into production, as well as business development and financing. With this background, Eurocine Vaccines has specialized on bridging the gap between innovation and market within the vaccine industry.
How it works?